The committed equity financing facility (CEFF) allows Jazz Pharmaceuticals to raise capital, at its discretion, to support the company’s commercial, product development and general corporate activities. Under the
The Court dismissed Johnson & Johnson’s lawsuit, found that the company’s NIR stent did not infringe one patent of Johnson & Johnson, and found that the other Johnson
The purpose of the offering is to enhance the company’s balance sheet. Certain officers and directors of Javelin will participate in this offering. The closing of the offering
The company reported net income of $33.7 million ($0.13 per diluted share) in the quarter ended March 31, 2008, compared with a net loss of $4.5 million ($0.02
Net loss for the three-month period ended March 31, 2008, was $6.7 million or $0.52 per share as compared to a net loss of $3.7 million or $0.31
Affymax’s total revenues for the quarter ended March 31, 2008 were $16.7 million compared to $7.3 million for the quarter ended March 31, 2007. The increase in revenue
Revenues for the quarter totaled $14.8 million compared to revenues of $17.6 million for the same period in 2007. Revenues primarily reflect reimbursement by the company’s collaborator, Wyeth,
NovoSeven RT- the new formulation of NovoSeven Coagulation Factor VIIa (Recombinant) – contains sucrose and L-Methionine, which allow for storage at room temperature. This is helpful for health-care
With the recent launch of over 1,600 new products in the areas of neuroscience, cancer biology, immunology, inflammation and arthritis, diabetes and vision research, ABR-Affinity BioReagents’s portfolio of
The ‘Fortify’ study met all primary and secondary endpoints, demonstrating that the product was able to maintain adequate testosterone levels within all of the pharmacokinetic parameters agreed with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.